flosequinan (Manoplax) Report issue

Small molecule Withdrawn
ChEMBL Drug Central KEGG MeSH PubChem

Active Ingredient History

NOW
  • Now
Flosequinan is a vasodilator developed for the treatment of heart failure. The drug was marketed under the name Manoplax, however it was withdrawn by the FDA decision since it increased congestive heart failure symptoms. The exact mechanism of flosequinan action is unknown, but there are studies reporting the inhibition of PDE3 activity.   NCATS

Chemistry

  • SMILES: CN1C=C([S+](C)[O-])C(=O)C2=C1C=C(F)C=C2
  • InChIKey: UYGONJYYUKVHDD-UHFFFAOYSA-N
  • Mol. Mass: 239.266
  • ALogP: 1.42
  • ChEMBL Molecule:
    flosequinan  
More Chemistry

Pharmacology

  • Mechanism of Action:
  • Multi-specific: Missing data
  • Black Box: No
  • Availability: Missing data
  • Delivery Methods: Missing data
  • Pro Drug: No

Alternative names

7-fluoro-1-methyl-3-methylsulfinyl-4-quinoline | bts 49465 | bts-49465 | flosequinan | flosequinon | manoplax

Organizations (1)

Research & Development (0)

Organization Org Type FDA approvals Clinical Trials involvement Org ID Force Sort

Marketing (1)

Organization Org Type FDA approvals Clinical Trials involvement Org ID Force Sort

Indications (1)

Approved Indications (1)


 

Heart Failure (approved 1992)

Experimental Indications - Clinical Trial Phases 1-4 (1)


 

Heart Failure ()

Feedback

Data collection and curation is an ongoing process for CDEK - if you notice any information here to be missing or incorrect, please let us know! When possible, please include a source URL (we verify all data prior to inclusion).

Report issue